RxDoctor Payments Data

Cary Fitchmun, MD

Family Medicine · Pismo Beach, CANPI 1982614616

Payments from drug & device makers

$1,964in general payments, 2019–2025

Across 92 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$253
  • Boehringer Ingelheim$241
  • Galderma Laboratories, L.p.$177
  • Amgen$167
  • Novo Nordisk$141
  • Inspire Medical Systems, Inc.$138
  • plus $847 from 14 others

What the payments were for

  • Food & beverage$1,964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,964 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$167,877
Medicare patients
210
Services billed
2,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$66,717
MounjaroTirzepatide51$55,915
OzempicSemaglutide31$44,928
XareltoRivaroxaban41$43,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$42,125
JanuviaSitagliptin Phosphate43$42,023
FarxigaDapagliflozin Propanediol33$24,490
TrulicityDulaglutide20$19,143
Spiriva RespimatTiotropium Bromide34$17,489
CreonLipase/Protease/Amylase16$15,847
Praluent PenAlirocumab20$9,680
JardianceEmpagliflozin14$8,587
SynthroidLevothyroxine Sodium73$6,738
Rosuvastatin Calcium398$5,294
SymbicortBudesonide/Formoterol Fumarate14$3,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$23$75,05971 claims
PfizerEliquis$253$66,71784 claims
Novo NordiskOzempic$141$44,92831 claims
Johnson & JohnsonXarelto$95$43,32941 claims
GSKTrelegy Ellipta$52$42,12539 claims
MerckJanuvia$80$42,02343 claims
Boehringer IngelheimSpiriva Respimat, Jardiance$241$26,07648 claims
AbbVieCreon, Synthroid$122$22,58589 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Pismo Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →